Caris Life Sciences today introduced its Right‑In‑Time (RIT) platform, a comprehensive solution that couples whole‑exome sequencing, whole‑transcriptome sequencing, and immunohistochemistry to generate a 23,000‑gene profile. The platform automatically matches each profile to a portfolio of more than 30 biomarker‑driven clinical trials and over 80 biopharmaceutical partners, enabling oncologists to identify relevant studies in a single, streamlined workflow.
The RIT system is engineered to move patients from profiling to enrollment in as few as five days. It operates across a network of more than 600 community oncology sites and 2,200 investigators nationwide, directly addressing the geographic gap that leaves 70% of U.S. counties without active cancer trials. With 85% of U.S. cancer patients receiving care in community settings, the platform positions Caris to bring investigational therapies to the majority of patients who currently lack local access.
Caris’s launch of RIT adds a new revenue stream and reinforces its role as a precision‑oncology partner. The company has already generated over 1,016,000 molecular tumor profiles and 740,000 matched profiles as of December 31, 2025, and the RIT solution builds on that extensive clinico‑genomic database. The initiative aligns with Caris’s broader strategy, which includes early cancer detection through Caris Detect and AI‑driven insights that support data‑centric decision making.
David Spetzler, President of Caris Life Sciences, emphasized the importance of comprehensive profiling and trial matching: "Comprehensive molecular profiling gives oncologists a complete picture of each patient's disease, which is essential for identifying the most effective treatment options. When that profiling is paired with a system that matches patients to relevant clinical trials, we can significantly expand the range of therapeutic possibilities available to every patient." He added, "Every patient diagnosed with cancer deserves a treatment plan informed by the molecular profile of their disease."
By bringing biomarker‑driven studies directly to community oncology practices, RIT expands trial access, accelerates patient enrollment, and positions Caris to capture growth in a rapidly evolving precision‑oncology market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.